At a glance
- Originator Elan Pharmaceuticals
- Class Small molecules
- Mechanism of Action Integrin alpha4beta1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 14 Sep 2000 New profile
- 14 Sep 2000 Preclinical development for Multiple sclerosis in USA (Unknown route)